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Introduction
Adenoviral vectors are the most efficient system of in vivo gene delivery and are widely used for gene therapy in basic research and clinical trials. [1] [2] [3] [4] [5] Yet, a growing body of evidence suggests that viral gene expression is associated with vector immunogenicity that limits the application of this vector system. 6, 7 While the cellular immune response limits the duration of transgene expression, the humoral response may reduce the therapeutic efficacy of repeated vector administration. 8 Thus, the immunological response to adenoviral vectors results in transient expression of transgene products (Ͻ2-3 weeks) and resistance to repeat systemic administration of the vectors in animal models. There is, however, evidence that some of these problems can be solved by modulating host immune responses. Prolonged transgene expression has been demonstrated in newborn or immunocompromised mice. 6 Likewise, chronic immunosuppression with cyclosporine prolongs transgene expression of adenovirally mediated factor IX replacement in hemophiliac dogs.
of immunity with subsequent resistance to further gene therapy remains a potential problem. Efforts have also been made to develop strategies for efficient repeated administration of adenoviral vectors. For example, partial immune ablation using cytokines or CTLA4-Ig leads to persistent adenoviral gene expression in mouse lung and liver. 10, 11 High-dose cyclophosphamide administered around the time of initial immunization in mice can reportedly reduce the development of neutralizing antibodies and virally directed cytotoxic T lymphocytes (CTLs) . 12 Yet, even though these findings demonstrated the feasibility of repeated administration in immunocompetent animals and contributed greatly to our understanding of the basic biological response in adenovirally mediated gene therapy, they have not been directly applied to humans in the clinical setting, partly because the agents required are not clinically available or given at a clinically acceptable dosage. We hypothesize that commonly used chemotherapeutic agents for cancer therapy can suppress the immune response to adenoviral vectors, thus allowing effectively repeated in vivo administration of the vectors, at clinically useful dosages. We report that etoposide at clinically acceptable dosages can suppress the formation of neutralizing antibodies and CTLs to adenovirus and result in successful intratumor transgene expression in immunized animals. 
Results
Etoposide and cyclophosphamide suppress the neutralizing antibody response to adenoviral vectors High-dose cyclophosphamide can reportedly suppress the humoral immune response to adenoviral vectors, resulting in effective repeated administration of the vectors. 12 To test whether a similar effect could be achieved at a lower, clinically applicable dose in a tumor model, cyclophosphamide was administered intraperitoneally (i.p.) at dosages of 2 or 10 mg/kg/day to C3H mice according to the time-course outlined in Figure 1 . Etoposide, a topoisomerase II inhibitor commonly used in cancer therapy, was also tested at the same dosages. C3H mice were immunized with 1 × 10 9 plaque forming units (p.f.u.) of the E1-deleted adenovirus Ad5/dl312 i.p. The sera were collected before and 28 days after the intraperitoneal injection, and the levels of neutralizing antibodies were determined. Etoposide at 2 mg/kg/day significantly suppressed the neutralizing antibody response by a median of 16-fold when compared with untreated control mice, whereas etoposide at 10 mg/kg/day completely prevented antibody formation in four of five mice (P Ͻ 0.05).
At a daily dose of 10 mg/kg, cyclophosphamide decreased the formation of neutralizing antibodies by a median of eight-fold when compared with untreated control mice (Table 1 ). Cyclophosphamide at a lower dosage of 2 mg/kg/day did not suppress the humoral response. Figure 2 . Specific lysis of Ad5-infected targets was demonstrated by lymphocytes harvested from the spleens of immunized mice. Nonimmunized mice were used as negative controls. Ad5-specific CTLs were markedly suppressed in animals treated with etoposide at 2 or 10 mg/kg/day or with cyclophosphamide at 10 mg/kg/day (P Ͻ 0.05, ANOVA). The lower dosage of cyclophosphamide (2 mg/kg/day) did not suppress Ad5-specific CTL response.
Etoposide and cyclophosphamide enhance transgene expression in vivo following intratumoral injection in immunized mice
To test whether treatment with etoposide and cyclophosphamide would increase the transgene expression after intratumoral injection of adenoviral vectors in immunocompetent mice, subcutaneous tumors were established
Figure 2 Cytotoxic T lymphocyte response in (a) cyclophosphamide-treated mice and (b) etoposide-treated mice. The dosages are indicated inside each graph. (ć, ) Target cells infected with Ad5/dl312; (ȣ, ̅) mock-infected target cells; (, ̅) effector cells from immunized and drug-treated animals; (ć, ȣ) effector cells from immunized and untreated animals.
by injecting 1 × 10 7 1422 cells per mouse in the flanks of C3H mice at day 14 following immunization. After 2 weeks, tumors 1-2 cm in diameter were injected with Ad5/CMV/␤-gal at 1 × 10 9 p.f.u. per tumor in 100 l solution. The mice were killed 48 h after the intratumoral injection, and the tumors were collected for X-gal staining for ␤-galactosidase. The area of blue cell staining was determined by image analysis and compared for each treatment group (Figure 3 ). Representative sections from each treatment group are illustrated in Figure 4 . While only trace levels of transgene expression were observed in the tumors from immunized mice left untreated or treated with cyclophosphamide at 2 mg/kg/day, significantly increased transgene expression was found in the tumors from mice treated with etoposide at 2 or 10 mg/kg/day or with cyclophosphamide at 10 mg/kg/day.
Chemotherapy was well tolerated by mice and myelosuppression was seen only at high doses of etoposide Like many other chemotherapeutic agents, etoposide and cyclophosphamide can be toxic. To estimate the potential treatment toxicity, changes in body weight and the amount of myelosuppression in mice during the administration of the drugs were monitored. The weights were not significantly different between treated and untreated groups (data not shown). White blood cell (WBC) counts and hemoglobin (Hg) levels were determined before treatment and at day 17 following immunization to determine the amount of myelosuppression resulting from chemotherapy. Only mice treated with a higher dosage of etoposide (10 mg/kg/day) had evidence of myelosuppression, with a mean WBC count of 5.2 × 10 3 and a mean Hg level of 8.5 g/dl (Table 2) . 
Discussion
Since DNA-damaging agents commonly used in cancer therapy are frequently immunosuppressive, we tested the hypothesis that chemotherapy delivered at the time of initial Ad5 vector administration could suppress the immune response to the adenovirus, thereby enhancing the level of transgene expression.
Cyclophosphamide is a nitrogen mustard-derived alkylating agent that interferes with DNA replication and RNA transcription. Cyclophosphamide is well absorbed orally and is indicated for use against many types of cancer including lymphoma, leukemia, lung cancer, breast cancer and ovarian cancer. It is also part of immunosuppression regimens following kidney, heart, liver and bone marrow transplantation. Oral maintenance dosages for cyclophosphamide range between 1 and 5 mg/kg/day; the patient's leukocyte count can serve as a guide for dosage adjustments. 13 Jooss et al 12 previously demonstrated that high-dose cyclophosphamide (70 mg/kg) given in several doses around the time of adenovirus administration diminishes inflammation, prolongs transgene expression, and prevents formation of neutralizing antibody following delivery of adenoviral vectors to mouse liver and lung in the C57BL/6 mouse strain. We found, however, that a much lower dose of cyclophosphamide (10 mg/kg) given on a daily basis was just as effective at suppressing the immune response to adenovirus and enhancing transgene expression after intratumoral injection of adenoviral vector in immunized mice.
Etoposide is a semisynthetic derivative of podophyllotoxin that causes an arrest at G 2 of the cell cycle. It inhibits DNA synthesis by interfering with the enzyme topoisomerase II and leads to cell death by apoptosis. 14, 15 Etoposide is indicated in the treatment of small cell lung cancer non-Hodgkin's lymphomas, leukemias, refractory testicular tumors, non-small cell lung cancer and Kaposi's sarcoma. Because etoposide lacks significant extramedullary toxicity, it has also been useful in high-dose chemotherapy with autologous bone marrow transplantation. 16 It is available in oral form and is tolerated as palliative monotherapy for patients with metastatic lung cancer at dosages of 1-2 mg/kg/day. 17, 18 Here we found etoposide to be effective in suppressing the immune response and enhancing transgene expression at a clinically acceptable dosage.
The role of etoposide in modulating immune response is not well documented. It is not commonly used for immunosuppression. Although the underlying mechanisms remain to be characterized, our finding that etoposide can effectively suppress both humoral and cellular immune response at a clinically acceptable dosage suggests that this drug may be potentially useful against other immune problems, such as those associated with autoimmune diseases, organ transplantations, and diseases where immune reaction is a major factor in pathogenesis. Our findings may also have implications for patients with cancer who are being treated on anticancer gene therapy protocols. Currently, protocols are aimed at patients with stage IV disease. Since many of these patients are concurrently treated with chemotherapeutic agents, a combination of adenovirally mediated tumor suppressor gene therapy with low-dose cyclophosphamide or etoposide could be incorporated into treatment regimens. By using such strategies, the immune responses to the adenoviral vector could be temporarily modulated, resulting in more effective anticancer gene therapy.
Our results show a correlation between immunosuppression and enhanced transgene expression in the second administration of adenoviral vector. However, we cannot exclude the involvement of other mechanisms besides immunosuppression in the enhancement of transgene expression. The major limiting toxicity for etoposide is myelosuppression, but our observation of no significant myelosuppression in the mice treated with etoposide at 2 mg/kg/day suggests that immunosuppression and myelosuppression may not be necessarily correlated. More recently, it was found that wild-type p53 could increase etoposide-induced cytotoxicity. 19 Further investigation of the role of etoposide in immunomodulation and adenovirally mediated gene transfer may therefore lead to the development of new strategies for cancer gene therapy and new applications of etoposide in other clinical settings.
Materials and methods

Cell lines and tumors
The cell lines 1422, 98-4, and 2237 (kindly provided by HN Ananthaswamy, MD Anderson Cancer Center, Houston, TX, USA) were derived from three separate tumors induced in female C3H/HeNCr(MTV−) mice by repeated exposure to UVB radiation. 20 H1299 cells are human large cell lung cancer cell lines that were generously provided by A Gazdar and J Minna (UT Southwestern Medical Center, Dallas, TX, USA). 21 H1299 cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 10 m glutamine, 100 U/ml penicillin, 100 g/ml streptomycin and 0.25 g/ml amphotericin B. Murine cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 10 m glutamine, 100 U/ml penicillin, 100 g/ml streptomycin and 0.25 g/ml amphotericin B (GIBCO- BRL, Grand Island, NY, USA) and incubated at 37°C in a 5% CO 2 incubator.
Recombinant adenovirus
The E1A-deleted adenovirus type 5 vector Ad5/dl312 (kindly provided by T Shenk, Howard Hughes Medical Institute, Princeton, NJ, USA) was used to immunize mice. The Ad5/CMV/␤-gal virus (kindly provided by F Graham, McMaster University, Hamilton, Ontario, Canada), which expresses the ␤-galactosidase marker gene, was used for intratumoral injection. Adenoviruses were prepared as previously described and purified by two rounds of cesium chloride ultracentrifugation. 22 A purified virus was mixed with 10% glycerol, dialyzed twice against buffer containing 10 mm Tris-HCl (pH 7.5), 1 mm MgCl 2 , and 10% glycerol at 4°C for 6 h, and then aliquoted and stored at −80°C until used. Viral titer was determined by ultraviolet-spectrophotometric analysis (viral particles/ml) and by plaque assay (p.f.u./ml). Final viral concentrations for in vitro and in vivo infections were made by diluting stock virus with phosphate-buffered saline (PBS). Adenovirus preparations were free of replication-competent adenovirus, as determined by previously described techniques. 23 
Analysis of in vitro gene transduction
The syngeneic cell lines, 1422, 98-4, and 2237 24, 25 were tested for their sensitivities to adenovirally mediated gene transduction. Twenty-four hours following infection with the Ad5/CMV/␤-gal virus, cells were washed with PBS at 4°C, fixed with ice-cold 1.25% glutaraldehyde, and stained with X-gal (5-bromo-4-chloro-3-indolyl-␤-dgalactoside; GIBCO-BRL) as described elsewhere. 26 Transduction efficiencies were determined in triplicate by measuring the percentage of cells staining positive (blue) for ␤-galactosidase activity (1000 cells counted per well). The 1422 cell line was the most permissive for adenovirus, with 56 and 93% transduction at the MOI of 10 and 100, respectively. This cell line was used in the subsequent in vivo experiments.
Animal studies C3H/HeNCr(MTV−) mice were purchased from the National Cancer Institute (NCI, Bethesda, MD, USA). All animals were maintained and all animal studies were performed according to institutional guidelines for the Animal Care Facility at MD Anderson Cancer Center. Adult C3H mice were immunized by an i.p. injection of 1 × 10 9 p.f.u. of Ad5/dl312 on day 0. Cyclophosphamide or etoposide (both from Bristol-Myers Squibb Oncology, Princeton, NJ, USA) was injected i.p. at dosages of 2 or 10 mg/kg/day beginning 5 days before immunization. Each treatment group included at least three animals. Additional mice that did not receive immunosuppressive chemotherapy or were not immunized were used as controls. On day 14, tumors from the 1422 cell line were established by subcutaneous injection of 1 × 10 7 cells suspended in 200 l serum-free media into the flanks of 6-to 8-week-old female C3H/HeNCr(MTV−) mice. After 14 days, tumors that had reached a size of approximately 200 mm 3 were injected with a single dose of 2 × 10 8 p.f.u. of Ad5/CMV/␤-gal. Each injection of purified virus was diluted in a total volume of 200 l PBS and administered in a single pass of a 30-gauge hypodermic needle, using gentle, constant infusion pressure. Animals were killed 48 h after tumor injection.
To assess the toxicity due to chemotherapy, animals were weighed before and after treatment. To assess the myelosuppressive effects of chemotherapy, Hg and WBC counts were measured in blood drawn from mice before treatment and at day 17.
Neutralizing antibody assay
Serum was heated at 56°C for 30 min to inactivate complement. Serial dilutions of serum in PBS (65 l, starting at 1:40) were incubated with an equal volume of Ad5/CMV/␤-gal at a concentration of 10 p.f.u./l for 60 min at 37°C in 96-well plates. A serum-virus mixture (100 l) was then added on to 24-well plates containing 1 × 10 4 H1299 cells (a human lung carcinoma cell line permissive to the adenovirus) per well. After 24 h of incubation at 37°C, the cells were fixed and stained for ␤-galactosidase activity. The number of blue cells was counted in each well. The maximum number of blue cells was determined by incubating the plated H1299 cells with virus alone. The neutralizing antibody titer was then determined as the dilution producing a 50% reduction in the maximum number of blue cells.
Cytotoxic T lymphocyte (CTL) assay
For the CTL assays, mice were killed 16 days after immunization. Splenocytes from three mice in each treatment group were pooled, and a single cell suspension was made. Lymphocytes were isolated on a FicollHypaque gradient, washed twice, and then plated in 24-well plates at 2 × 10 6 cells per well. Lymphocytes were restimulated in vitro for 4 days with either purified Ad5/dl312 (MOI 1) or 1422 cells infected with Ad5/dl312 (MOI 75) and irradiated to 250 cGy. Additional splenocytes from each group were incubated with interleukin 2 (IL-2) at a concentration of 100 U/ml as a positive control for cytotoxicity.
1422 Target , and 2% X-gal solution and counter stained with nuclear fast red (Sigma, St Louis, MO, USA) for 5 min. Quantitative assessment of lacZ gene expression (blue cells) was determined by digital image analysis (BioScan, Version 4.10; Optimas, Bothell, WA, USA). Three sections from each tumor were analyzed, including the center and the section 2 mm on either side of the center, and an average area of blue cell staining in square microns was determined for each tumor. Tumors that were not injected with Ad5/CMV/␤-gal were used as negative controls to rule out nonspecific staining.
Statistical analysis
Statistical analyses were performed by analysis of variance using the SPSS software package licensed to the University of Texas MD Anderson Cancer Center. P values Ͻ0.05 were considered significant.
